60 Degrees Pharmaceuticals (SXTP) updates legal opinion for at-the-market stock program

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to report that it obtained and filed an updated legal opinion from Sichenzia Ross Ference Carmel LLP covering shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright & Co., LLC.

The opinion, filed as Exhibit 5.1 with an associated consent in Exhibit 23.1, confirms the validity of shares that may be sold under the program and addresses related legal matters. The company states that this updated opinion does not change the existing terms of the at-the-market program.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/13/2026 - 05:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 13, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) filed an updated legal opinion of counsel regarding the shares of common stock issued and sold under its “at-the-market” equity offering program (the “ATM Program”) pursuant to the Sales Agreement, dated September 5, 2025, entered into by and between the Company and HC Wainwright & Co., LLC. The updated opinion is attached hereto as Exhibit 5.1.

The updated legal opinion does not affect the terms of the ATM Program but provides confirmation regarding the validity of the shares that may be sold under the program and certain matters related to the offering of shares under applicable law.

The foregoing description of the opinion does not purport to be complete and is qualified in its entirety by reference to the full text of the opinion filed as Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits

(a) Exhibits

Number		Description
5.1		Opinion of Sichenzia Ross Ference Carmel LLP
23.1		Consent of Sichenzia Ross Ference Carmel LLP (included in the opinion filed as Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.

Date: March 13, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR

FAQ

What did 60 Degrees Pharmaceuticals (SXTP) report in this Form 8-K?

60 Degrees Pharmaceuticals reported that it filed an updated legal opinion covering shares issued and sold under its at-the-market equity offering program. The opinion confirms the validity of these shares and addresses certain legal matters without changing the program’s existing terms.

What is the purpose of the updated legal opinion for SXTP’s ATM program?

The updated legal opinion is intended to confirm the validity of common shares that may be sold under SXTP’s at-the-market equity offering program. It also addresses certain matters related to offering those shares under applicable law, while leaving the program’s contractual terms unchanged.

Who issued the updated legal opinion for 60 Degrees Pharmaceuticals (SXTP)?

The updated legal opinion was issued by Sichenzia Ross Ference Carmel LLP. Their opinion is filed as Exhibit 5.1, with a related consent included as Exhibit 23.1, and it addresses the validity and legal treatment of shares sold under the at-the-market program.

Does the updated legal opinion change SXTP’s at-the-market equity offering terms?

The company states that the updated legal opinion does not affect the terms of its at-the-market equity offering program. Instead, it provides legal confirmation regarding the validity of shares that may be sold and clarifies certain legal aspects of the offering process.

What is the relationship between SXTP and HC Wainwright in the ATM program?

SXTP’s at-the-market equity offering program operates under a Sales Agreement dated September 5, 2025, between the company and HC Wainwright & Co., LLC. HC Wainwright serves as the sales agent for selling common stock under this program pursuant to that agreement.

Which exhibits were filed with this SXTP Form 8-K?

The filing includes Exhibit 5.1, which is the legal opinion of Sichenzia Ross Ference Carmel LLP, and Exhibit 23.1, the related consent included within that opinion. It also includes Exhibit 104, the cover page interactive data file in Inline XBRL format.

Filing Exhibits & Attachments

5 documents